Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer
- 18 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 112 (5), 725-727
- https://doi.org/10.1007/s12185-020-02918-6
Abstract
Chemotherapy is the mainstay of treatment for advanced pancreatic cancer however, due to possible myelotoxicity, it is used with caution in patients with thrombocytopenia, especially when severe. TPO-receptor agonists have been employed for chemotherapy-induced thrombocytopenia, however treatment with TPO-receptor agonists to allow chemotherapy in patients with inherited thrombocytopenia has not been reported so far. We report the first successful use of eltrombopag to prevent chemotherapy-induced thrombocytopenia in a patient with MHY9-related disorder and pancreatic cancer. Treatment with eltrombopag allowed to attain a safe and stable platelet count for several months sufficient to permit chemotherapy and to allow the patient to undergo endoscopic placement of a biliary stent with no bleeding complications.Keywords
Funding Information
- Fondazione Umberto Veronesi (.)
This publication has 9 references indexed in Scilit:
- Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopeniaAmerican Journal of Hematology, 2019
- Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trialHaematologica, 2019
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThe New England Journal of Medicine, 2018
- Romiplostim for management of chemotherapy-induced thrombocytopeniaSupportive Care in Cancer, 2014
- First Successful Use of Eltrombopag Before Surgery in a Child With MYH9-Related ThrombocytopeniaPEDIATRICS, 2013
- Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease SyndromePLOS ONE, 2012
- Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical ObservationsInternational Journal of Medical Sciences, 2012
- Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutationsBlood, 2010
- A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumorsCurrent Medical Research and Opinion, 2010